ALB and liver cancer: Additionally, as human serum albumin (HSA) nanoparticles are becoming a non-toxic drug delivery system, and thus their inclusion for drug nanoencapsulation was also addressed in vitro (human liver cancer HepG2 cells) and in vivo (H22 tumor-bearing mice).